Moxodin tablets p/o 0.2mg №10×3

Name:
Moksodin
Description:
Tablets, coated white, cylindrical, biconvex. The main active ingredient Moxonidine Form of releaseCoated tablets Dosage Moxonidine 0.2 mg Special instructions Moxonidine should not be used in children and adolescents under 18 years of age due to the lack of data on safety and efficacy. Pharmacotherapeutic group Antiadrenergic agents of central action. Imidazoline receptor agonists. Indications for use Arterial hypertension. Dosage and Administration The recommended dose is one 0.2 mg tablet per day, in the morning. If the therapeutic effect is insufficient after 4 weeks of treatment, the dose may be increased to 0.4 mg once a day or in two divided doses at the beginning of a meal (there are 0.4 mg tablets). It is recommended not to exceed 0.4 mg per dose and 0.6 mg per day (in two divided doses). In patients with moderate renal impairment (glomerular filtration rate (GFR) 30 to 60 ml/min) or severe renal insufficiency (GFR 15 to 30 ml/min), the initial dose is 0.2 mg per day. In patients on hemodialysis, the daily dose is 0.2 mg. If necessary, and if it is well tolerated, the dose may be increased to 0.4 mg of moxonidine per day. Moxodine can be taken with or without food. Use during pregnancy and lactation There are no clinical data on the treatment of pregnant women with moxonidine. In animal studies, direct or indirect negative effects on pregnancy, fetal / embryonic development, childbirth or postnatal development have not been established. Assign Moxodin to pregnant women is allowed only in cases of emergency, after a thorough assessment of the risk-benefit ratio, when the benefit to the mother outweighs the potential risk to the fetus. Moxonidine passes into breast milk. Breastfeeding women during the period of treatment are advised to stop breastfeeding or discontinue the drug. Precautions: Cases of varying degrees of atrioventricular block have been reported in patients treated with moxonidine. In these cases, the effect of moxonidine on slowing atrioventricular conduction cannot be excluded. Therefore, it is recommended to use with caution in patients predisposed to the development of atrioventricular blockade. Particular care should be taken when using moxonidine in patients with first degree atrioventricular block to avoid bradycardia. Moxonidine should not be used in patients with a high degree of atrioventricular block. Due to the lack of documented clinical experience, moxonidine is not recommended for depression. Moxonidine should be used with caution in patients with severe ischemic heart disease or unstable angina due to limited experience with its use in this group of patients. Since moxonidine is mainly excreted by the kidneys, special care is recommended when used in patients with renal insufficiency. In these patients, dosage adjustments are recommended, especially at the start of treatment. The daily initial dose is 0.2 mg. If it is necessary to interrupt the combined treatment with beta-blockers and moxonidine, first gradually stop treatment with beta-blockers, then, after a few days, moxonidine. To date, no rebound effects on blood pressure readings have been observed after discontinuation of moxonidine treatment. However, it is required to gradually reduce the dose over 2 weeks, to avoid sudden discontinuation of treatment. The elderly may be more sensitive to the cardiovascular effects of antihypertensive drugs. Therefore, treatment should be initiated at a low dose and dose increases should be made carefully to prevent serious adverse reactions. Moxodine contains lactose. Its use is not recommended in patients with galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (rare hereditary disease). Interaction with other drugs Not recommended combinations: With alcohol. Increased sedative effect of alcohol-based drugs. It is recommended to refrain from driving vehicles and working with dangerous mechanisms due to lack of attention. Avoid drinking alcoholic beverages and medicines containing alcohol. With beta-blockers for heart failure. The central decrease in sympathetic tone and the vasodilating effects of centrally acting antihypertensives are dangerous in patients with heart failure receiving beta-blockers and vasodilators. Combinations requiring precautionary measures: With baclofen. Increased risk of hypotension. Blood pressure should be monitored and dose adjusted if necessary. With beta-blockers (except esmolol). Significant increase in blood pressure in the event of abrupt discontinuation of a centrally acting antihypertensive drug. Avoid sudden withdrawal of moxonidine. Combinations to be considered: With amifostine. Increased risk of hypotension, especially orthostatic. With non-steroidal anti-inflammatory drugs (NSAIDs). Based on extrapolation of data from indomethacin, it is possible to reduce the antihypertensive effect by inhibiting vasodilatory prostaglandins and fluid retention. with alpha-blockers used in urology or antihypertensive alpha-blockers. Increased hypotensive effect. Increased risk of developing orthostatic hypotension. With neuroleptics, tricyclic antidepressants. Increased hypotensive risk, especially orthostatic. With nitrates and their derivatives. Increased risk of hypotension, including orthostatic. Co-administration of moxonidine with drugs that have a sedative effect, such as morphine derivatives (analgesics, antitussives and substitution therapy), antipsychotics, barbiturates, benzodiazepines and hypnotics that are not related to benzodiazepine derivatives (for example, meprobamate), sedatives, antidepressants (amitriptyline, doxepin, mianserin, mirtazapine, trimipramine), antihistamines (H1 receptor blockers with sedative effect), central antihypertensive agents, thalidomide, accompanied by an increase in central depression. Due to the possible decrease in attention, it is necessary to avoid driving vehicles and using dangerous mechanisms. The simultaneous use of other antihypertensive products enhances the antihypertensive effect of moxonidine. Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive drugs. Thus, the simultaneous use of tricyclic antidepressants with moxonidine is not recommended. Moxonidine moderately improves cognitive impairment in patients receiving lorazepam. Moxonidine is eliminated by tubular excretion. Interactions with other agents that are eliminated by tubular excretion cannot be ruled out. Contraindications Hypersensitivity to the active substance or any of the excipients. Sick sinus syndrome or sinoatrial block. Bradycardia (with a resting heart rate of less than 50 bpm). Atrioventricular blockade of the 2nd or 3rd degree. Heart failure. Composition 1 tablet Moxonidine 0.2 mg contains: active substance: moxonidine – 0.2 mg excipients: microcrystalline cellulose, povidone K 30, sodium starch glycolate (type A), magnesium stearate, lactose monohydrate shell: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc. Overdose There are reports of several cases of non-fatal overdose, when doses up to 19.6 mg were used simultaneously. Symptoms: headache, sedation, drowsiness, pronounced decrease in blood pressure, dizziness, fatigue, asthenia, bradycardia, dry mouth, vomiting and pain in the epigastric region. A short-term increase in blood pressure, tachycardia, and hyperglycemia are also potentially possible. There is no specific antidote. In the event of a decrease in blood pressure, it is recommended to restore the volume of circulating blood due to the introduction of fluid and the introduction of dopamine. Bradycardia can be treated with atropine. Alpha-adrenergic antagonists may reduce or eliminate the paradoxical hypertensive effects of moxonidine overdose. In case of overdose, consult a doctor! Side effects From the side of the central nervous system: often – headache, dizziness (vertigo), drowsiness; infrequently – fainting. From the side of the cardiovascular system: infrequently – a pronounced decrease in blood pressure, orthostatic hypotension, bradycardia. From the digestive system: very often – dry mouth; often – diarrhea, nausea, vomiting, dyspepsia. From the skin and subcutaneous tissues: often – skin rash, itching; infrequently – angioedema. On the part of the psyche: often – insomnia; infrequently – nervousness. On the part of the organ of hearing and labyrinth disorders: infrequently – ringing in the ears. From the musculoskeletal system: often – back pain; infrequently – pain in the neck. On the part of the body as a whole: often – asthenia; infrequently – peripheral edema. Storage conditionsStore at a temperature not exceeding 25 °C. Keep out of the reach of children! Buy Moxodin tablets p/o 0.2 mg No. 10×3